Clinical Trials for Mesothelioma Patients: Vorinostat vs. Placebo
Read about a current clinical trial being conducted to study Vorinostat in patients who have been diagnosed with mesothelioma or lung cancer. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.
Vorinostat (MK0683, SAHA) Versus Placebo in Advanced Malignant Pleural MesotheliomaPurpose:
This is a Phase III a study which incorporates an initial Phase II component to determine the safety, tolerability, and anti-tumor effectiveness of an oral investigational drug suberoylanilide hydroxamic acid, in the treatment of advanced malignant pleural Mesothelioma.
Revised (20-Dec-2007)
Requisite Conditions:
Mesothelioma
Lung Cancer
Intervention:
Drugs: Suberoylanilide Hydroxamic Acid (SAHA); Placebo (unspecified)
Study Phase, Type and Design:
Phase II (Mesothelioma) and Phase III (Lung Cancer) Interventional study. Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment
Official Title:
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Advanced Malignant Pleural Mesothelioma Previously Treated With Systemic Chemotherapy
If you or a loved one has been diagnosed with an Asbestos illness like mesothelioma, lung cancer or asbestosis, complete the form on this page to get a FREE and prompt review of your case by a leading Asbestos attorney. Weitz & Luxenberg is a leading mesothelioma law firm with a substantial history of success in asbestos exposure cases.
Patient inclusion criteria for Vorinostat drug study on mesothelioma